Evidence map›Paper›PMID 35496538›Full record

ArticleRSC advances2020

Essential oil loaded pectin/chitosan nanoparticles preparation and optimization

Olivia A Attallah, Amro Shetta, Fatma Elshishiny, Wael Mamdouh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 77 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Proapoptotic Activity ofMolecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Olivia A AttallahDepartment of Chemistry, School of Sciences and Engineering (SSE), The American University in Cairo (AUC) AUC Avenue, P.O. Box 74 New Cairo 11835 Egypt wael_mamdouh@aucegypt.edu.ORCID https://orcid.org/0000-0002-6449-5108
Amro ShettaDepartment of Chemistry, School of Sciences and Engineering (SSE), The American University in Cairo (AUC) AUC Avenue, P.O. Box 74 New Cairo 11835 Egypt wael_mamdouh@aucegypt.edu.
Fatma ElshishinyDepartment of Chemistry, School of Sciences and Engineering (SSE), The American University in Cairo (AUC) AUC Avenue, P.O. Box 74 New Cairo 11835 Egypt wael_mamdouh@aucegypt.edu.
Wael MamdouhDepartment of Chemistry, School of Sciences and Engineering (SSE), The American University in Cairo (AUC) AUC Avenue, P.O. Box 74 New Cairo 11835 Egypt wael_mamdouh@aucegypt.edu.
New Cairo Academy · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the continuous search for effective cancer treatments, we here report a novel anticancer nanoparticulate system composed of jasmine oil (JO), an essential oil with proven anticancer activity and pectin/chitosan composite nanoparticles (Pec/CS NPs) as encapsulating materials to overcome JO's solubility and sensitivity problems using a green ionotropic gelation method. Pec/CS/JO NPs were formulated using Box-Behnken design (BBD) to estimate the interactions and effects of studied formulation variables on particle size, zeta potential and encapsulation efficiency to develop an optimized Pec/CS nanoformulation. The nano-encapsulation system preserved the consistency of total phenolic contents in JO and amended its thermal stability by 1.64 fold. The antioxidant potency of JO was enhanced after encapsulation by 96.28%. Consequently, the cytotoxic activity of bare Pec/CS NPs, pure JO and encapsulated JO in Pec/CS NPs against (MCF-7) breast cancer cells and (L-929) normal cells was evaluated using MTT assay. Encapsulated JO was more potent than pure JO with ≈13 fold improvement in anticancer activity, whereas the cell viability of normal cells wasn't affected but was rather enhanced when treated with Pec/CS NPs.

Identifiers

PMID35496538
PMCPMC9049973
OpenAlexW3007093832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.